Bcal Diagnostics Ltd
BCAL Diagnostics Limited, a screening and diagnostic company, engages in developing a novel blood screening test to improve the diagnosis and monitoring of breast cancer. It develops BREASTESTplus, a first-in-class blood test designed to be used alongside standard mammogram in breast cancer screening. The company also develops BREASTEST, BCAL Diagnostics, and BCAL Dx. The company was incorporated… Read more
Bcal Diagnostics Ltd (BDX) - Total Assets
Latest total assets as of December 2025: AU$7.17 Million AUD
Based on the latest financial reports, Bcal Diagnostics Ltd (BDX) holds total assets worth AU$7.17 Million AUD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Bcal Diagnostics Ltd - Total Assets Trend (2017–2024)
This chart illustrates how Bcal Diagnostics Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Bcal Diagnostics Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Bcal Diagnostics Ltd's total assets of AU$7.17 Million consist of 72.6% current assets and 27.4% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 45.6% |
| Accounts Receivable | AU$6.93K | 0.1% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$2.71 Million | 27.4% |
| Intangible Assets | AU$18.31K | 0.2% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Bcal Diagnostics Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bcal Diagnostics Ltd's current assets represent 72.6% of total assets in 2024, a decrease from 99.9% in 2017.
- Cash Position: Cash and equivalents constituted 45.6% of total assets in 2024, down from 55.2% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is property, plant & equipment at 27.4% of total assets.
Bcal Diagnostics Ltd Competitors by Total Assets
Key competitors of Bcal Diagnostics Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF
|
USA | $4.51 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
NSN Co. Ltd
KQ:031860
|
Korea | ₩60.96 Billion |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
Bcal Diagnostics Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Bcal Diagnostics Ltd generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Bcal Diagnostics Ltd is currently not profitable relative to its asset base.
Bcal Diagnostics Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.67 | 6.54 | 1.36 |
| Quick Ratio | 3.67 | 6.54 | 1.49 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | AU$3.48 Million | AU$ 7.08 Million | AU$ 232.06K |
Bcal Diagnostics Ltd - Advanced Valuation Insights
This section examines the relationship between Bcal Diagnostics Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 16.95 |
| Latest Market Cap to Assets Ratio | 1.04 |
| Asset Growth Rate (YoY) | -19.2% |
| Total Assets | AU$9.91 Million |
| Market Capitalization | $10.33 Million USD |
Valuation Analysis
Above Book Valuation: The market values Bcal Diagnostics Ltd's assets above their book value (1.04 x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Bcal Diagnostics Ltd's assets decreased by 19.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Bcal Diagnostics Ltd (2017–2024)
The table below shows the annual total assets of Bcal Diagnostics Ltd from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | AU$9.91 Million | -19.21% |
| 2023-12-31 | AU$12.27 Million | +46.52% |
| 2022-12-31 | AU$8.37 Million | -20.95% |
| 2021-12-31 | AU$10.59 Million | +156.27% |
| 2020-12-31 | AU$4.13 Million | +404.23% |
| 2019-12-31 | AU$819.55K | +51.67% |
| 2018-12-31 | AU$540.34K | -3.51% |
| 2017-12-31 | AU$560.02K | -- |